Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.
Company profile
Ticker
UROV
Exchange
Website
CEO
James A. Robinson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Urovant Sciences, Inc. • Urovant Treasury Holdings, Inc. • Urovant Sciences Treasury, Inc. • Urovant Holdings Limited • Urovant Sciences GmbH ...
UROV stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
8 Apr 21
EFFECT
Notice of effectiveness
1 Apr 21
SC 13E3/A
Going private transaction (amended)
29 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 21
POS AM
Prospectus update (post-effective amendment)
29 Mar 21
25-NSE
Exchange delisting
29 Mar 21
8-K
Sumitovant Biopharma Completes Acquisition of Urovant Sciences
29 Mar 21
8-K
Submission of Matters to a Vote of Security Holders
24 Mar 21
Transcripts
UROV
Earnings call transcript
2020 Q2
2 Nov 20
UROV
Earnings call transcript
2020 Q2
2 Nov 20
UROV
Earnings call transcript
2020 Q2
2 Nov 20
UROV
Earnings call transcript
2020 Q1
13 Aug 20
UROV
Earnings call transcript
2019 Q4
18 Jun 20
UROV
Earnings call transcript
2019 Q3
13 Feb 20
UROV
Earnings call transcript
2019 Q2
9 Nov 19
UROV
Earnings call transcript
2019 Q1
13 Aug 19
UROV
Earnings call transcript
2018 Q4
13 Jun 19
UROV
Earnings call transcript
2018 Q3
13 Feb 19
Latest ownership filings
Financial summary
Quarter (USD) | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 20 | Mar 19 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.74 mm | 73.74 mm | 73.74 mm | 73.74 mm | 73.74 mm | 73.74 mm |
Cash burn (monthly) | 1.04 mm | 4.92 mm | 15.64 mm | 13.66 mm | 15.61 mm | 11.82 mm |
Cash used (since last report) | 41.53 mm | 197.37 mm | 627.43 mm | 547.80 mm | 626.14 mm | 474.07 mm |
Cash remaining | 32.21 mm | -123.62 mm | -553.68 mm | -474.05 mm | -552.40 mm | -400.33 mm |
Runway (months of cash) | 31.1 | -25.1 | -35.4 | -34.7 | -35.4 | -33.9 |
Institutional ownership, Q2 2021
70.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 22.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sumitomo Chemical | 22.96 mm | $0.00 |